Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease

被引：0
|
作者：
White, William B. [1 ]
Gunawardhana, Lhanoo [2 ]
机构：
[1] Univ Connecticut, Sch Med, Cardiol, Farmington, CT USA
[2] Takeda Pharmaceut Int, Deerfield, IL USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2242
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Febuxostat or Allopurinol in Patients with Gout Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)
    Alten, R.
    Mischkewitz, M.
    Nitschmann, S.
    INTERNIST, 2020, 61 (05): : 530 - 532
  • [2] Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
    White, William B.
    Saag, Kenneth G.
    Becker, Michael A.
    Borer, Jeffrey S.
    Gorelick, Philip B.
    Whelton, Andrew
    Hunt, Barbara
    Castillo, Majin
    Gunawardhana, Lhanoo
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13): : 1200 - 1210
  • [3] MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH RECURRENT GOUT, CARDIOVASCULAR AND CHRONIC KIDNEY DISEASE, INITIATING ON ALLOPURINOL OR FEBUXOSTAT
    Foody, J.
    Turpin, R.
    Tidwell, B. A.
    Lawrence, D. F. Eisenberg
    Schulman, K. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 374 - 374
  • [4] General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout
    Saag, Kenneth
    Becker, Michael A.
    White, William B.
    Whelton, Andrew
    Borer, Jeffrey
    Gorelick, Philip
    Hunt, Barbara
    Castillo, Majin
    Gunawardhana, Lhanoo
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [5] A COMPARATIVE EVALUATION OF THE HEALTH ECONOMIC OUTCOMES OF FEBUXOSTAT AND ALLOPURINOL IN GOUT PATIENTS WITH CHRONIC KIDNEY DISEASE
    Mitri, G.
    Wittbrodt, E. T.
    Turpin, R. S.
    Costa, L. A.
    Schulman, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 445 - 445
  • [6] CArdiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular ComoRbiditiES
    White, William B.
    Chohan, Saima
    Dabholkar, Aruna
    Hunt, Barbara
    Jackson, Robert
    AMERICAN HEART JOURNAL, 2012, 164 (01) : 14 - 20
  • [7] Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)
    Foody, JoAnne
    Turpin, Robin
    Tidwell, Beni
    Schulman, Kathy
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [8] Meta-analysis assessing cardiovascular outcomes with febuxostat versus allopurinol for patients with gout
    Patoulias, D.
    Boulmpou, A.
    Tranidou, A.
    Nikolaidis, A.
    Papadopoulos, C. E.
    Vassilikos, V.
    Bakatselos, S.
    Damianidis, G.
    Doumas, M.
    EUROPEAN HEART JOURNAL, 2021, 42 : 3264 - 3264
  • [9] Febuxostat vs allopurinol for gout: cardiovascular safety
    Reactions Weekly, 2021, 1858 (1) : 9 - 9
  • [10] Cardiovascular Risk in Gout Patients Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)
    Mueller-Wieland, D.
    Nitschmann, S.
    INTERNIST, 2018, 59 (11): : 1224 - 1228
12345